AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32338932
Drug: Integrative cognitive‐affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive‐affective therapy for BED (ICAT‐BED)
Trial: 32338932
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help cognitive-behavioral therapy (CBTgsh)
Trial: 33092527
Drug: Intravesical dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical dexmedetomidine instillation (0.5 μg/kg and normal saline 20 mL)
Trial: 34429002
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with allergen extracts of D. pteronyssinus and D. farinae (50/50%) in SQ-HDM SLIT tablets
Trial: 35367007
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for 17 cycles
Trial: 34187535
Drug: basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic treatment + Gegen Qinlian decoction placebo + Erbai drink placebo
Trial: 38634928
Drug: Pembrolizumab (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (second-line therapy)
Trial: 32886108
Drug: 70 g
RxNorm normalized name: alcohol .70 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 g mycoprotein (31.5 g protein; MYCO; n = 10)
Trial: 32886108
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g BCAA-enriched mycoprotein (18.7 g protein; ENR; n = 9)
Trial: 32808025
Drug: Bi-anodal tDCS
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-anodal tDCS over the PFC regions (2 mA, 20 minutes, twice daily for 5 weeks)
Trial: 35039258
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (erythromycin sequential therapy plus azithromycin)
Trial: 33712076
Drug: Ephedrine 0.6
RxNorm normalized name: pseudoephedrine 0.66 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.6 mg/kg
Trial: 33712076
Drug: Ephedrine 0.8
RxNorm normalized name: ephedrine 0.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.8 mg/kg
Trial: 33712076
Drug: Ephedrine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 1.0 mg/kg
Trial: 33712076
Drug: Ephedrine 1.2
RxNorm normalized name: ephedrine 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 1.2 mg/kg
Trial: 33712076
Drug: Ephedrine 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 1.4 mg/kg
Trial: 33712076
Drug: Ephedrine 0.1
RxNorm normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.1 mg/kg (reference dose)
Trial: 35848821
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 ml triamcinolone 40 mg/ml)
Trial: 33672963
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g acacia gum
Trial: 33672963
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g acacia gum
Trial: 33672963
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g acacia gum (control)
Trial: 36318050
Drug: One-session treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session treatment
Trial: 35493437
Drug: iCT-SAD (internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCT-SAD (internet Cognitive Therapy programme)
Trial: 35600872
Drug: Tibetan herbal
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tibetan herbal pain-relieving plaster (Tibetree Pain-Relieving Plaster) applied daily for 14 days
Trial: 35600872
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied daily for 14 days
Trial: 33320850
Drug: Whey protein-based
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein-based multiingredient nutritional supplement
Trial: 33288467
Drug: Online Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Cognitive Behavioral Therapy (CBT) with telephone support
Trial: 33288467
Drug: Online Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Cognitive Behavioral Therapy (CBT) without telephone support
Trial: 33707061
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg mRNA-1273
Trial: 33707061
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg mRNA-1273
Trial: 33707061
Drug: Both 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 50 µg and 100 µg mRNA-1273
Trial: 34439165
Drug: Neoadjuvant induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus anti-HER2 therapy.
Trial: 34439165
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with CpCR plus ypN0 after neoadjuvant treatment.
Trial: 35115359
Drug: Benfotiamine 300
RxNorm normalized name: Benfotiamine 300mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine 300 mg two times a day for 12 months
Trial: 33844575
Drug: Deferred vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred vaccination via blinded crossover (original vaccine group receives placebo and vice versa)
Trial: 33844575
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving the efficacious vaccine after initial trial
Trial: 34406870
Drug: Whole breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole breast irradiation (radiation therapy [RT])
Trial: 35271241
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training in addition to drug therapy
Trial: 32185662
Drug: Plecanatide 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plecanatide 0.3 mg
Trial: 32185662
Drug: Plecanatide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plecanatide 3.0 mg
Trial: 32185662
Drug: Plecanatide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plecanatide (0.3 mg and 3.0 mg)
Trial: 35033928
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (liraglutide) after 10 days
Trial: 35033928
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (liraglutide) after 12 weeks
Trial: 33187535
Drug: Clinical standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical standard of care (nutritionist and/or physical therapy referrals)
Trial: 32311110
Drug: Higher than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher than 10 mg dapagliflozin
Trial: 33155105
Drug: Iohexol administration
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iohexol administration at standard dose during coronary CT angiography (CCTA)
Trial: 34900443
Drug: Manual Therapy+Exercise
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy+Exercise (MT+Exercise) Group
Trial: 34023199
Drug: Combination model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination model incorporating radiomics signature with two clinical biomarkers
Trial: 34482102
Drug: Anlotinib 12
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg combined with camrelizumab 200 mg every 3 weeks
Trial: 34482102
Drug: Anlotinib 8
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 8 mg combined with camrelizumab 200 mg every 3 weeks
Trial: 35803626
Drug: Monthly community-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly community-based testing for anaemia
Trial: 34729992
Drug: high-dose acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose acetylcholine (10−4 mol/L)
Trial: 34729992
Drug: low-dose acetylcholine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose acetylcholine
Trial: 34729992
Drug: high-dose acetylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose acetylcholine
Trial: 33542928
Drug: Prodom-assisted urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodom-assisted urokinase treatment (PAUT)
Trial: 33542928
Drug: Syringe-assisted urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe-assisted urokinase treatment (SAUT)
Trial: 33542928
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (TT)
Trial: 34294478
Drug: Nonavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonavalent vaccine HPV types
Trial: 35785574
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (30 s tDCS treatment)
Trial: 34120651
Drug: remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remogliflozin etabonate 500 mg BID with metformin 2000 mg
Trial: 34120651
Drug: remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remogliflozin etabonate 750 mg BID with metformin 2000 mg
Trial: 34120651
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID with metformin 2000 mg
Trial: 33098117
Drug: Sodium azulene
RxNorm normalized name: azulene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium azulene sulphonate hydrate 0.02% ophthalmic solution
Trial: 32279363
Drug: FIFA 11+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIFA 11+ program executed twice a week for 20 weeks
Trial: 35935332
Drug: Positive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive therapy and full perfusion therapy (combined with conventional therapy)
Trial: 32757218
Drug: 3-month personalized
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month personalized treatment considering LPR characteristics at impedance-pH monitoring
Trial: 36266483
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection method (LIM) during ESD
Trial: 33484307
Drug: No-PDS group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-PDS group (bi-cortical CC-ligament reconstruction only)
Trial: 34636521
Drug: Bioelectric Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioelectric Muscle Activation (BMA) system (Accufit)TM; treatment regimen: four 30-minute sessions
Trial: 32101630
Drug: Lifestyle development
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle development program conducted over 7 months with group activities once a month and daily individual activities.
Trial: 33181142
Drug: 2% IDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% IDL lotion applied over 2 weeks
Trial: 36078584
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (HIIT-G)
Trial: 33461385
Drug: Chitin-glucan (CG)
RxNorm normalized name: Chitin
DrugBank: Chitin (DB15142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitin-glucan (CG) 4.5 g
Trial: 33461385
Drug: Maltodextrin (placebo)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (placebo) 4.5 g
Trial: 33245242
Drug: Low-dose corticosteroid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticosteroid therapies
Trial: 33710427
Drug: Transvaginal uterosacral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal uterosacral ligament suspension (USLS)
Trial: 34952812
Drug: Intravaginal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal electrical stimulation for 8 weeks, weekly 20-minute sessions with voluntary contraction attempts during the last 10 minutes of each session.
Trial: 34826341
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure goal of <120 mm Hg)
Trial: 35235550
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine (Gardasil or Gardasil 9)
Trial: 35235550
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (AC) - Avaxim, a hepatitis A vaccine
Trial: 32833136
Drug: Eribulin in
RxNorm normalized name: eriBULin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin in combination with trastuzumab and pertuzumab
Trial: 34195102
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot supplement
Trial: 35110416
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus anthracycline or non-anthracycline chemotherapy
Trial: 33641042
Drug: Anthracycline-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based therapy
Trial: 34518245
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of both interventions
Trial: 34898896
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 30 mg/day
Trial: 34898896
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone 600 mg/day
Trial: 36841463
Drug: Levonorgestrel 52
RxNorm normalized name: LEVONORGESTREL 52MG INSERT INTRAUTERINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 52 mg IUD
Trial: 36841463
Drug: Levonorgestrel 19.5
RxNorm normalized name: levonorgestrel 19.5 MG Intrauterine System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 19.5 mg IUD
Trial: 35213459
Drug: Peritoneal lavage
RxNorm normalized name: Peritoneal Lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritoneal lavage using 10 L normal saline
Trial: 35980169
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for asymptomatic bacteriuria (AB)
Trial: 35980169
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for asymptomatic bacteriuria (AB)
Trial: 36401652
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine eyedrops, administered once nightly for 1 year
Trial: 36401652
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine eyedrops, administered for 6 months after crossover
Trial: 33658764
Drug: Neostigmine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 40 µg/kg
Trial: 33744202
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions written by general practitioners (GPs)
Trial: 33744202
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions written by nurses
Trial: 33744202
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions for skin and soft-tissue infection
Trial: 33744202
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions for lower respiratory-tract infection
Trial: 33744202
Drug: Ciprofloxacin, amoxicillin-clavulanate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, amoxicillin-clavulanate, and cefalexin
Trial: 33087111
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg daily orally at 21:00 for 28 days
Trial: 33087111
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily orally at 21:00 for 28 days
Trial: 32131070
Drug: Suicide prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suicide prevention nursing competency program (120 minutes, twice a week for 3 weeks)
Trial: 32769757
Drug: Fezolinetant 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 15, 30, 60, or 90 mg BID or 30, 60, or 120 mg QD
Trial: 35029612
Drug: Gluten Friendly™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten Friendly™ bread (3 g)
Trial: 35029612
Drug: Gluten Friendly™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten Friendly™ bread (6 g)
Trial: 35029612
Drug: Gluten Friendly™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten Friendly™ bread (0 g)
Trial: 32075507
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (bolus 1.5 mg kg−1 followed by 1.5 mg kg−1 h−1 for 3 hours)
Trial: 36115968
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L PEG + LB
Trial: 34034273
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L PEG
Trial: 33887208
Drug: SARS-CoV-2 sclamp
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 sclamp vaccine at 5 μg
Trial: 33887208
Drug: SARS-CoV-2 sclamp
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 sclamp vaccine at 15 μg
Trial: 33887208
Drug: SARS-CoV-2 sclamp
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 sclamp vaccine at 45 μg (two doses)
Trial: 33887208
Drug: SARS-CoV-2 sclamp
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 sclamp vaccine at 45 μg (single dose)
Trial: 33887208
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of sclamp vaccine at any concentration
Trial: 33887208
Drug: SARS-CoV-2 sclamp
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 sclamp vaccine at any dose
Trial: 35659655
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no PBM treatment).
Trial: 32570678
Drug: Artificial intelligence
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence conversational agent technologies and behavioral activation therapy techniques
Trial: 35184228
Drug: JUUL2 prototype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL2 prototype 18 mg/mL nicotine
Trial: 35184228
Drug: JUUL2 prototype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL2 prototype 40 mg/mL
Trial: 35184228
Drug: IQOS 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IQOS 18 mg/g
Trial: 35184228
Drug: JUUL 59
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL 59 mg/mL
Trial: 33184328
Drug: Cholecalciferol (100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (100,000 IU single dose)
Trial: 34130339
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for preventing preeclampsia and small-for-gestational-age births in high-risk women
Trial: 34130339
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for secondary prevention of cardiovascular disease
Trial: 34130339
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for recurrent venous thromboembolism
Trial: 34130339
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing regimen or evening intake of aspirin
Trial: 34130339
Drug: Shorter aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shorter aspirin duration strategies after percutaneous coronary interventions